View clinical trials related to Sclerosis.
Filter by:The Expanded Access Program will provide access and assess the safety of AMX0035 for the treatment of people living with ALS.
The objective of this early access program (EAP) is to provide access to tofersen to eligible participants with amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene prior to an alternative access mechanism in order to address a high unmet medical need in this population.